Norges Bank
KNSA icon

Norges Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Norges Bank’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,947
Closed -$406K – 2235
2021
Q1 		$406K Sell
21,947
-45,649
-68% -$934K ﹤0.01% 2099
2020
Q4 		$1.19M Sell
67,596
-55,625
-45% -$977K ﹤0.01% 2011
2020
Q3 		$1.89M Buy
123,221
+82,395
+202% +$1.55M ﹤0.01% 1973
2020
Q2 		$1.04M Buy
40,826
+22,750
+126% +$475K ﹤0.01% 2008
2020
Q1 		$280K Buy
+18,076
New +$283K ﹤0.01% 2034

Other funds holding KNSA

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Norges Bank's KNSA Position: Q2 2021 in Review

Norges Bank sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2021, closing a stake of 21,947 shares — an estimated $406K sold.

Norges Bank first reported a position in KNSA in Q1 2020 and held it in 5 quarters. The position peaked at $1.89M in Q3 2020. 102 funds tracked by Wall St. Rank hold KNSA as of Q2 2021.

  • Norges Bank reported no remaining Kiniksa Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Norges Bank sold 21,947 Kiniksa Pharmaceuticals shares in Q2 2021, an estimated $406K.
  • Norges Bank first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 5 quarters.
  • Norges Bank's Kiniksa Pharmaceuticals position peaked at $1.89M in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2021.

Based on Norges Bank's 13F filing for Q2 2021, filed 10 Aug 2021.